Imagion Biosystems Ltd (ASX: IBX) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Imagion Biosystems Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$2.07 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
35.65 million
Earnings per share
-0.184
Dividend per share
N/A
Year To Date Return
-91.27%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Imagion Biosystems Ltd (ASX: IBX)
Latest News
Healthcare Shares
The Imagion Biosystems (ASX:IBX) share price just exploded by 60%. Here's why
Share Gainers
The Imagion Biosystems (ASX:IBX) share price leapt 40% in 2 days this week. What's happening?
Healthcare Shares
Imagion Biosystems (ASX:IBX) share price soars 13% on quarterly update
Share Gainers
Imagion (ASX:IBX) share price zips 38% higher. Here's why
Healthcare Shares
Imagion (ASX:IBX) share price up 1,166% in a year pursuing 'radiation-free' cancer tech
IBX ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Imagion Biosystems Ltd
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. Its principal continuing activities consisted of Nanotechnology; Biotechnology; Cancer Diagnostics; and Medical Imaging using Magnetic Resonance and Superparamagnetic Relaxometry. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and medical imaging using Superparamagnetic Relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.
IBX Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 15 Nov 2024 | $0.05 | $0.00 | 0.00% | 164,412 | $0.05 | $0.05 | $0.05 |
| 14 Nov 2024 | $0.05 | $0.00 | 0.00% | 453,924 | $0.05 | $0.05 | $0.05 |
| 13 Nov 2024 | $0.05 | $0.00 | 0.00% | 6,250 | $0.05 | $0.05 | $0.05 |
| 12 Nov 2024 | $0.05 | $0.00 | 0.00% | 176,044 | $0.05 | $0.05 | $0.05 |
| 11 Nov 2024 | $0.05 | $0.00 | 0.00% | 358,054 | $0.05 | $0.05 | $0.05 |
| 08 Nov 2024 | $0.05 | $0.00 | 0.00% | 62,234 | $0.05 | $0.05 | $0.05 |
| 07 Nov 2024 | $0.05 | $-0.01 | -19.23% | 783,421 | $0.05 | $0.05 | $0.04 |
| 06 Nov 2024 | $0.05 | $0.00 | 0.00% | 153,347 | $0.05 | $0.05 | $0.05 |
| 05 Nov 2024 | $0.05 | $0.00 | 0.00% | 176,483 | $0.05 | $0.05 | $0.05 |
| 04 Nov 2024 | $0.05 | $0.00 | 0.00% | 6,216 | $0.05 | $0.05 | $0.05 |
| 01 Nov 2024 | $0.05 | $0.00 | 0.00% | 113,672 | $0.05 | $0.05 | $0.05 |
| 31 Oct 2024 | $0.05 | $0.00 | 0.00% | 93,828 | $0.06 | $0.06 | $0.05 |
| 30 Oct 2024 | $0.05 | $-0.01 | -16.67% | 128,502 | $0.06 | $0.06 | $0.05 |
| 29 Oct 2024 | $0.06 | $0.00 | 0.00% | 1,306,954 | $0.06 | $0.08 | $0.05 |
| 28 Oct 2024 | $0.06 | $0.01 | 20.41% | 997,952 | $0.05 | $0.07 | $0.05 |
| 25 Oct 2024 | $0.05 | $0.00 | 0.00% | 552,353 | $0.05 | $0.05 | $0.05 |
| 24 Oct 2024 | $0.05 | $-0.01 | -15.63% | 373,396 | $0.06 | $0.06 | $0.05 |
| 23 Oct 2024 | $0.06 | $0.01 | 19.23% | 971,284 | $0.05 | $0.07 | $0.05 |
| 22 Oct 2024 | $0.05 | $0.01 | 22.22% | 636,359 | $0.05 | $0.06 | $0.05 |
| 21 Oct 2024 | $0.05 | $0.00 | 0.00% | 87,808 | $0.05 | $0.05 | $0.05 |
| 18 Oct 2024 | $0.04 | $0.00 | 0.00% | 128,868 | $0.04 | $0.04 | $0.04 |
| 17 Oct 2024 | $0.04 | $0.00 | 0.00% | 101,814 | $0.03 | $0.04 | $0.03 |
| 16 Oct 2024 | $0.04 | $0.00 | 0.00% | 63 | $0.04 | $0.04 | $0.04 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 22 Aug 2024 | Brett Mitchell | Issued | 1,250,000 | $48,750 |
Issue of securities. 1,250,000 Rights
|
| 22 Aug 2024 | Robert Proulx | Issued | 2,000,000 | $78,000 |
Issue of securities. 2,000,000 Unlisted Performance Rights, As per announcement on 23-08-2024
|
| 27 Jun 2024 | Brett Mitchell | Buy | 20,908 | $1,744 |
On-market trade.
|
| 19 Jun 2024 | Brett Mitchell | Buy | 88,569 | $7,971 |
On-market trade.
|
| 18 Jun 2024 | Brett Mitchell | Buy | 120,216 | $10,537 |
On-market trade.
|
| 17 Jun 2024 | Brett Mitchell | Buy | 91,551 | $7,173 |
On-market trade.
|
| 14 Jun 2024 | Brett Mitchell | Buy | 199,664 | $14,816 |
On-market trade.
|
| 20 Dec 2023 | Isaac Bright | Issued | 187,500 | $64,687 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Ms Melanie Jaye Leydin | Company Secretary Non-Execufive Director | May 2024 |
Ms Leydin has 25 years experience in the accounting profession and over 15 years as a company secretary with experience in relation to public company responsibilities, including ASX and ASIC compliance, control and implementations of corporate governance, statutory financial reporting, re-organisation of Companies and shareholder relations.
|
| Mr Brett Anthony Mitchell | Non-Executive Director | Jun 2024 |
Mr Mitchell is a corporate finance executive with more than 15 years of experience in ASX listed companies leading transactions in the biopharmaceutical, mining, energy and tech industries. He has been involved in the founding, financing, and management of both private and publicly-listed companies, including recently as a director of ASX listed lithium developer Delta Lithium Ltd (DLI), the dual ASX-LSE listed medical cannabis company Argent Biopharma Ltd (RGT), and is currently Executive Chairman of ASX listed Javelin Minerals Ltd (ASX:JAV) and Non-Executive Chairman of Uvre Limited (ASX :UVA).
|
| Mr Robert Romeo Proulx | Executive DirectorExecutive Chairman | Dec 2016 |
Mr Proulx's previous employment experience includes President / General Manager for Silicon Biosystems and a career in marketing and sales management with more than 25 years' experience in the computer, life science and medical diagnostics industries. Some of Robert's other relevant experience include : Vice President Marketing and Sales for Nanogen Inc.; Senior Vice President of Marketing and Business Development at Gene Logic; and General Manager, Life Sciences at IGEN International Inc.
|
| Geoff Hollis | Chief Financial Officer / Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Citicorp Nominees Pty Limited | 1,211,054 | 3.71% |
| HSBC Custody Nominees (Australia) Limited | 713,860 | 2.19% |
| Mr Haojie Li | 610,438 | 1.87% |
| Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient> | 542,204 | 1.66% |
| Skicorp Pty Ltd <Gulabovski Sf A/C> | 294,002 | 0.90% |
| Mr Xucong Wu | 268,032 | 0.82% |
| The Board Of Regents Of The University Of Texas System | 263,227 | 0.81% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 253,633 | 0.78% |
| Mr Anestis Lazaridis | 243,595 | 0.75% |
| E & W Nominee Pty Ltd <Liang Family Super Fund A/C> | 240,238 | 0.74% |
| Mr Kassem Bedran | 239,556 | 0.73% |
| Wh & Pr Pty Ltd <Robhoo Unit A/C> | 225,000 | 0.69% |
| Dr Reza Hayatbakhsh & Mrs Fahimeh Motamedi | 200,000 | 0.61% |
| Finclear Services Pty Ltd <Superhero Securities A/C> | 197,150 | 0.60% |
| Bnp Paribas Noms Pty Ltd | 186,790 | 0.57% |
| Mr Robert Proulx | 154,082 | 0.47% |
| Timarc Nominees Pty Ltd | 150,000 | 0.46% |
| Long Tall Kathy Pty Ltd <Long Tall Kathy Family A/C> | 140,000 | 0.43% |
| Miss Hengdi Zhang | 135,794 | 0.42% |
| Miss Christine Chen | 135,000 | 0.41% |
